PolyTherics TheraPEGTM Patent Allowed in Europe
“Allowance of the patent that underpins our technology in therapeutic protein optimisation is a significant milestone for PolyTherics”, commented Dr. Keith Powell, CEO of PolyTherics. “The technology has already been licensed to several partners to develop and commercialise their therapeutic proteins in PEGylated form. For the future, we see great commercial opportunity in applying TheraPEG™ to microbially-expressed proteins, to undercut the timelines and costs associated with mammalian cell fermentation.”
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.